The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma Journal Article


Authors: Kim, H. R.; Ahn, J. R.; Lee, J. G.; Bang, D. H.; Ha, S. J.; Hong, Y. K.; Kim, S. M.; Nam, K. C.; Rha, S. Y.; Soo, R. A.; Riely, G. J.; Kim, J. H.; Cho, B. C.
Article Title: The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma
Abstract: Purpose: This study was designed to determine the relationship of cigarette smoking to the frequency and qualitative differences among KRAS mutations in lung adenocarcinomas from Korean patients. Materials and Methods: Detailed smoking histories were obtained from 200 consecutively enrolled patients with lung adenocarcinoma according to a standard protocol. EGFR (exons 18 to 21) and KRAS (codons 12/13) mutations were determined via direct-sequencing. Results: The incidence of KRAS mutations was 8% (16 of 200) in patients with lung adenocarcinoma. KRAS mutations were found in 5.8% (7 of 120) of tumors from never-smokers, 15% (6 of 40) from former-smokers, and 7.5% (3 of 40) from current-smokers. The frequency of KRAS mutations did not differ significantly according to smoking history (p=0.435). Never-smokers were significantly more likely than former or current smokers to have a transition mutation (G→A or C→T) rather than a transversion mutation (G→T or G→C) that is known to be smoking-related (p=0.011). In a Cox regression model, the adjusted hazard ratios for the risk of progression with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were 0.24 (95% CI, 0.14-0.42; p<0.001) for the EGFR mutation and 1.27 (95% CI, 0.58-2.79; p=0.537) for the KRAS mutation. Conclusion: Cigarette smoking did not influence the frequency of KRAS mutations in lung adenocarcinomas in Korean patients, but influenced qualitative differences in the KRAS mutations. © Yonsei University College of Medicine 2013.
Keywords: vasculotropin; adult; treatment outcome; aged; gene mutation; major clinical study; cigarette smoking; sorafenib; erlotinib; follow up; epidermal growth factor receptor; cohort analysis; genotype; smoking; questionnaire; lung adenocarcinoma; nucleotide sequence; gefitinib; egfr; kras; oncogene k ras; pulmonary adenocarcinoma; egfr-tyrosine kinase inhibitors; transition mutation; transversion mutation
Journal Title: Yonsei Medical Journal
Volume: 54
Issue: 4
ISSN: 0513-5796
Publisher: Yonsei University College of Medicine  
Date Published: 2013-07-01
Start Page: 865
End Page: 874
Language: English
DOI: 10.3349/ymj.2013.54.4.865
PROVIDER: scopus
PMCID: PMC3663229
PUBMED: 23709419
DOI/URL:
Notes: --- - "Export Date: 1 July 2013" - "CODEN: YOMJA" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Gregory J Riely
    462 Riely